The most powerful MRI in the world studies the effects of COVID and myalgic encephalomyelitis / brain fatigue.

Published Date: 15 Mar 2023

For the first time in the world, researchers at Griffith University have used ultra-high magnetic field (7 Tesla) MRI to examine how COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS ) affect the same brain.

Read Full News

Latest News

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Reframing Dyslexia: Ancient Genes, Modern Skill

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults With IDDs Face ‘Mental Health Crisis’

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Todays Updates

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

US CDC Deploys Staff to Curb South Carolina's Measles Outbreak

(Refiles to remove extraneous word years from first paragraph)

After FDA Declined Review, EMA Backs 1st Flu-COVID mRNA Vax

The Moderna vaccine will likely be available in Europe long before the US.

Saline Lavage Shows No Clinical Benefit in Pleural Infection

Saline lavage, alone or combined with intrapleural enzyme therapy, confers no clinically meaningful advantage over intrapleural enzyme therapy alone in patients with pleural infection.

Your Patient Doesn’t Like Your Accent or Color: Now What?

Many doctors facing racism from patients stay silent, doubting they’ll be heard. Experts share strategies for handling bias when institutions fall short.

Doravirine Plus Islatravir Matches Standard HIV Therapy

In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus islatravir shows efficacy and safety similar to standard ART regimens.

Peak Anti-HBs Level May Predict Protection in HIV Infection

Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.

Todays Updates

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

US CDC Deploys Staff to Curb South Carolina's Measles Outbreak

(Refiles to remove extraneous word years from first paragraph)

After FDA Declined Review, EMA Backs 1st Flu-COVID mRNA Vax

The Moderna vaccine will likely be available in Europe long before the US.

Saline Lavage Shows No Clinical Benefit in Pleural Infection

Saline lavage, alone or combined with intrapleural enzyme therapy, confers no clinically meaningful advantage over intrapleural enzyme therapy alone in patients with pleural infection.

Your Patient Doesn’t Like Your Accent or Color: Now What?

Many doctors facing racism from patients stay silent, doubting they’ll be heard. Experts share strategies for handling bias when institutions fall short.

Doravirine Plus Islatravir Matches Standard HIV Therapy

In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus islatravir shows efficacy and safety similar to standard ART regimens.

Peak Anti-HBs Level May Predict Protection in HIV Infection

Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.

Latest News

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

News All Time

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education Charuta Joshi, MD, Isabella Ciccone, MPH

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

Recommended News For You

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

Study suggests radiation therapy benefits misjudged when clinical factors alone guide breast cancer treatment

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Recommended Articles For You

Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights 

Respiratory Ramifications of Systemic Disease: A Comprehensive Review 

Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence 

The Ins and Outs of Glossectomy: What You Need to Know  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

2.

Independent Risk Factors for "Deaths of Despair" Found.

3.

Minimally invasive prostate cancer treatment shows success in first patient

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Cancer After Weight Loss; How Older Adults Use the Healthcare System.

1.

How to Prevent Tumor Lysis Syndrome in Cancer Patients

2.

Respiratory Ramifications of Systemic Disease: A Comprehensive Review

3.

Clinical Analysis of Prostate Cancer

4.

Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology

5.

Surprising Symptoms of Prostate Cancer: What You Need to Know

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

2.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

4.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

5.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot